Loading
Ternary Complex · Journal article
Journal of Enzyme Inhibition and Medicinal Chemistry · August 4, 2026
Raises a question worth testing. It does not answer one.
This is a narrative review that integrates PROTAC design principles—including linker properties, warhead topology, E3 ligase selection, and biological context—into a proposed conceptual framework for optimizing both degradation efficiency and developability. The review does not present novel experimental evidence or clinical data, but rather synthesizes existing literature to guide medicinal chemistry decision-making in PROTAC development.
Narrative review article.
First PROTAC now approved; many additional candidates in clinical evaluation PROTACs convert transient ternary recognition into ubiquitin-mediated elimination, enabling pharmacology not solely dependent on sustained target occupancy Linker length, rigidity, and exit vectors together with warhead recognition topology determine formation of cooperative, ubiquitination-competent ternary complex
No primary experimental data, clinical trial results, or quantitative efficacy/safety metrics provided PROTACs convert transient ternary recognition into ubiquitin-mediated elimination, enabling pharmacology not solely dependent on sustained target occupancy
The source did not state who this applies to in practice.
This is a narrative review article that synthesizes existing knowledge and proposes a conceptual framework for PROTAC design; it does not present new primary experimental data, clinical outcomes, or empirical validation of its recommendations.
As stated by the source record.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Proteolysis-targeting chimaeras (PROTACs) couple target recognition to ubiquitin-dependent degradation, but their translation requires coordinated optimisation of degradation efficiency and developability. This review frames PROTAC design as a context-dependent medicinal chemistry problem rather than modular assembly of a warhead, linker and ubiquitin ligase (E3) recruiter. Linker length, rigidity, and exit vectors, together with warhead recognition topology, determine whether binary binding can form a cooperative, ubiquitination-competent ternary complex. Warhead binding mode further affects catalytic turnover and cellular degradation. Linker-free designs and disclosed clinical PROTAC structures show that beyond Rule of Five property control remains central to exposure. Conditional linkers and E3 ligase choice add biological constraints through stimulus-responsive activation, recruiter tractability, E3 expression, localisation, pathway biology, and safety liabilities. This review integrates these principles into a framework for PROTAC design. The framework aligns productive ternary complex assembly, effective exposure and biological-context compatibility within the intended therapeutic context.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.